María José Moreno Martínez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
María José Moreno Martínez has a total of 283 co-authors. Here are the top co-authors by number of shared publications:
- Manuel José Moreno Ramos
Rheumatology, Virgen de la Arrixaca University Hospital, El Palmar, Spain
7 shared publications Carlos Rodríguez-Lozano
3 shared publicationsElena Peñas Martínez
Hospital Rafael Méndez, Lorca, Murcia, España
3 shared publicationsLuis Francisco Linares Ferrando
Reumatología, Hospital Rafael Méndez, Lorca, Murcia, España; Reumatología, Hospital Virgen de la Arrixaca, Murcia, España
3 shared publicationsA.D.C. Haro-Martinez
Rheumatology, Hopital Rafael Méndez, Lorca, Spain
2 shared publicationsAna Pérez-Gómez
Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain
2 shared publications
Latest Publications
- Open Access
- 11 January 2026
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 77, 152923
Disease activity and hyperuricemia predict the development of cardiovascular events in patients with Psoriatic Arthritis: results of the 10-year prospective evaluation in the CARMA cohort
- 11 January 2026
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 77, 152923
Open AccessDisease activity and hyperuricemia predict the development of cardiovascular events in patients with Psoriatic Arthritis: results of the 10-year prospective evaluation in the CARMA cohort
- 30 May 2024
- Published by Elsevier in Reumatología Clínica (English Edition)
- Vol. 20 (5) , 254-262
Delphi consensus on the use of telemedicine in rheumatology: RESULTAR study
- 30 May 2024
- Published by Elsevier in Reumatología Clínica (English Edition)
- Vol. 20 (5) , 254-262
Delphi consensus on the use of telemedicine in rheumatology: RESULTAR study
- Open Access
- 5 March 2024
- Published by Springer Nature in BMC Rheumatology
- Vol. 8 (1) , 1-17
Methotrexate treatment strategies for rheumatoid arthritis: a scoping review on doses and administration routes
Background: To describe the evidence of methotrexate (MTX) initiation strategies in patients with rheumatoid arthritis (RA) and, in the case of non-responders, analyse the efficacy and safety of route and dose optimisation. Methods: We conducted a comprehensive scoping review of randomised controlled trials according to PRISMA Scoping Reviews Checklist and the framework proposed by Arksey and O’Malley. PubMed, EMBASE, and Cochrane were searched without language restriction, and hand searches of relevant articles were examined. Results: We identified 1,367 potentially eligible studies, of which 12 were selected based on the titles and abstracts and then on the full-length articles. In naïve-MTX patients, a linear dose-response relationship for starting dose was found between 5 mg/m2/week (7.5–10 mg/week) and 10 mg/m2/week (15–22 mg/week), without toxicity correlation. A higher initial dose of MTX (25 mg vs. 15 mg) was more effective, resulting in fewer dose increases due to ineffectiveness and more dose reductions due to higher remission rates. There was also a trend towards increased gastrointestinal toxicity. Comparing different routes of administration of MTX, subcutaneous MTX showed a statistically higher ACR20 response (85%) in comparison with oral MTX (77%) (p < 0.05). The clinical efficacy and safety of accelerated and conventional start MTX regimens were comparable between 7.5 and 15 mg with a 2,5 mg dose increase every two weeks. In RA patients who have failed the initial treatment with MTX, the stepwise increase in MTX doses is associated with a higher ACR20 response and sustained remission rate than other strategies. In MTX non-responders, optimisation to SC MTX was associated with improvements in ACR20 and ACR50 rates with similar toxicity between groups. In the early RA patients subgroup, SC MTX showed higher ACR20 response rates than oral MTX, and intensive oral methods have a much higher sustained remission rate, shorter mean time to remission, and better clinical disease activity measures than conventional treatments. Conclusions: Higher starting doses of MTX and initial subcutaneous MTX made better performance in improving the ACR20 response, although the clinical effectiveness and safety of other MTX start regimens are comparable. This scoping review provides evidence in support of optimising MTX treatment in terms of route and dose prior to concluding that MTX treatment in RA patients has failed.
- 5 March 2024
- Published by Springer Nature in BMC Rheumatology
- Vol. 8 (1) , 1-17
Open AccessMethotrexate treatment strategies for rheumatoid arthritis: a scoping review on doses and administration routes
Background: To describe the evidence of methotrexate (MTX) initiation strategies in patients with rheumatoid arthritis (RA) and, in the case of non-responders, analyse the efficacy and safety of route and dose optimisation. Methods: We conducted a comprehensive scoping review of randomised controlled trials according to PRISMA Scoping Reviews Checklist and the framework proposed by Arksey and O’Malley. PubMed, EMBASE, and Cochrane were searched without language restriction, and hand searches of relevant articles were examined. Results: We identified 1,367 potentially eligible studies, of which 12 were selected based on the titles and abstracts and then on the full-length articles. In naïve-MTX patients, a linear dose-response relationship for starting dose was found between 5 mg/m2/week (7.5–10 mg/week) and 10 mg/m2/week (15–22 mg/week), without toxicity correlation. A higher initial dose of MTX (25 mg vs. 15 mg) was more effective, resulting in fewer dose increases due to ineffectiveness and more dose reductions due to higher remission rates. There was also a trend towards increased gastrointestinal toxicity. Comparing different routes of administration of MTX, subcutaneous MTX showed a statistically higher ACR20 response (85%) in comparison with oral MTX (77%) (p < 0.05). The clinical efficacy and safety of accelerated and conventional start MTX regimens were comparable between 7.5 and 15 mg with a 2,5 mg dose increase every two weeks. In RA patients who have failed the initial treatment with MTX, the stepwise increase in MTX doses is associated with a higher ACR20 response and sustained remission rate than other strategies. In MTX non-responders, optimisation to SC MTX was associated with improvements in ACR20 and ACR50 rates with similar toxicity between groups. In the early RA patients subgroup, SC MTX showed higher ACR20 response rates than oral MTX, and intensive oral methods have a much higher sustained remission rate, shorter mean time to remission, and better clinical disease activity measures than conventional treatments. Conclusions: Higher starting doses of MTX and initial subcutaneous MTX made better performance in improving the ACR20 response, although the clinical effectiveness and safety of other MTX start regimens are comparable. This scoping review provides evidence in support of optimising MTX treatment in terms of route and dose prior to concluding that MTX treatment in RA patients has failed.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S24)
Mental health in Colombian dementia patients: the impact of COVID‐19
Background: The COVID‐19 pandemic related to the new coronavirus SARS‐CoV‐2 has generated new challenges in healthcare systems worldwide. In Colombia, different measures were adopted, such as preventive isolation, to reduce the number of infections considering its high transmissibility. However, this led to changes in the mental health of older individuals affected both by this confinement situation and by the consequences of the disease in this population group.Method: The objective is to determine if there are cognitive changes associated with the disease and confinement due to the new coronavirus infection in a sample of 70 individuals with dementia. To achieve this, an analysis of one of the COVID‐19 questionnaires proposed in the RedLat project is performed, in which relatives and patients report their perception of changes in their mental health. The impact of the confinement situation and the disease itself is analyzed.Result: In general, a significant change is found in the cognitive, affective, and social sphere of each individual with dementia.Conclusion: These findings are relevant as they allow for the proposal of alternative rehabilitation strategies following COVID‐19 and the generation of other mental health promotion programs in older individuals with cognitive impairment.References:Bombón‐Albán, P. E., & Suárez‐Salazar, J. V. (2022). Manifestaciones cognitivas y neuropsiquiátricas de COVID‐19 en el Adulto Mayor con y sin demencia: Revisión de la literatura. Revista de Neuro‐Psiquiatria, 85(2), 117‐126.Parra, M. A., Baez, S., Sedeño, L., Gonzalez Campo, C., Santamaría‐García, H., Aprahamian, I., … & Ibanez, A. (2021). Dementia in Latin America: paving the way toward a regional action plan. Alzheimer’s & Dementia, 17(2), 295‐313.Duran‐Aniotz, C., Sanhueza, J., Grinberg, L. T., Slachevsky, A., Valcour, V., Robertson, I., … & Ibáñez, A. (2022). The Latin American Brain Health Institute, a regional initiative to reduce the scale and impact of dementia. Russo, M. J., Cohen, G., Campos, J., & Allegri, R. F. (2021). COVID‐19 y adultos mayores con deterioro cognitivo:¿ puede influir el aislamiento social en la enfermedad?. Neurología Argentina, 13(3), 159‐169.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S24)
Open AccessMental health in Colombian dementia patients: the impact of COVID‐19
Background: The COVID‐19 pandemic related to the new coronavirus SARS‐CoV‐2 has generated new challenges in healthcare systems worldwide. In Colombia, different measures were adopted, such as preventive isolation, to reduce the number of infections considering its high transmissibility. However, this led to changes in the mental health of older individuals affected both by this confinement situation and by the consequences of the disease in this population group.Method: The objective is to determine if there are cognitive changes associated with the disease and confinement due to the new coronavirus infection in a sample of 70 individuals with dementia. To achieve this, an analysis of one of the COVID‐19 questionnaires proposed in the RedLat project is performed, in which relatives and patients report their perception of changes in their mental health. The impact of the confinement situation and the disease itself is analyzed.Result: In general, a significant change is found in the cognitive, affective, and social sphere of each individual with dementia.Conclusion: These findings are relevant as they allow for the proposal of alternative rehabilitation strategies following COVID‐19 and the generation of other mental health promotion programs in older individuals with cognitive impairment.References:Bombón‐Albán, P. E., & Suárez‐Salazar, J. V. (2022). Manifestaciones cognitivas y neuropsiquiátricas de COVID‐19 en el Adulto Mayor con y sin demencia: Revisión de la literatura. Revista de Neuro‐Psiquiatria, 85(2), 117‐126.Parra, M. A., Baez, S., Sedeño, L., Gonzalez Campo, C., Santamaría‐García, H., Aprahamian, I., … & Ibanez, A. (2021). Dementia in Latin America: paving the way toward a regional action plan. Alzheimer’s & Dementia, 17(2), 295‐313.Duran‐Aniotz, C., Sanhueza, J., Grinberg, L. T., Slachevsky, A., Valcour, V., Robertson, I., … & Ibáñez, A. (2022). The Latin American Brain Health Institute, a regional initiative to reduce the scale and impact of dementia. Russo, M. J., Cohen, G., Campos, J., & Allegri, R. F. (2021). COVID‐19 y adultos mayores con deterioro cognitivo:¿ puede influir el aislamiento social en la enfermedad?. Neurología Argentina, 13(3), 159‐169.
- Open Access
- 5 September 2022
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 9 (5) , 1-2
Correction to: Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry
- 5 September 2022
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 9 (5) , 1-2
Open AccessCorrection to: Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry
- Open Access
- 25 April 2022
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 9 (4) , 1031-1047
Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry
Rheumatic diseases are extensively managed with biological disease-modifying antirheumatic drugs (bDMARDs), but a notable proportion of patients withdraw in the long term because of lack of effectiveness, adverse events, or the patient’s decision. The present real-world analysis showed the effectiveness, retention, and safety data collected in the Spanish BIOBADASER registry for patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA, including ankylosing spondylitis (AS) and non-radiographic axSpA) treated with secukinumab, a human antibody against interleukin-17A (IL-17A), for more than 12 months. Six hundred and thirty-nine patients were analysed (350, 262, and 27 PsA, AS, and nr-axSpA patients, respectively). The results showed an improvement in the disease activity after 1 year of treatment, in terms of decreases of the mean Disease Activity Score 28 using C-reactive protein (DAS28-CRP), the mean Disease Activity Psoriatic Arthritis (DAPSA) score, swollen joint counts (SJC), and tender joint counts (TJC) in PsA patients and decreases in the mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the mean Ankylosing Spondylitis Disease Activity Score (ASDAS) in axSpA patients. This improvement was maintained or increased after 2 and 3 years of treatment, indicating that secukinumab is effective in both naïve and non-responder patients. Retention rates were higher when secukinumab was used as the first-line biological treatment, although they were also adequate in the second and third lines of treatment. Collected safety data were consistent with previous reports.
- 25 April 2022
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 9 (4) , 1031-1047
Open AccessReal-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry
Rheumatic diseases are extensively managed with biological disease-modifying antirheumatic drugs (bDMARDs), but a notable proportion of patients withdraw in the long term because of lack of effectiveness, adverse events, or the patient’s decision. The present real-world analysis showed the effectiveness, retention, and safety data collected in the Spanish BIOBADASER registry for patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA, including ankylosing spondylitis (AS) and non-radiographic axSpA) treated with secukinumab, a human antibody against interleukin-17A (IL-17A), for more than 12 months. Six hundred and thirty-nine patients were analysed (350, 262, and 27 PsA, AS, and nr-axSpA patients, respectively). The results showed an improvement in the disease activity after 1 year of treatment, in terms of decreases of the mean Disease Activity Score 28 using C-reactive protein (DAS28-CRP), the mean Disease Activity Psoriatic Arthritis (DAPSA) score, swollen joint counts (SJC), and tender joint counts (TJC) in PsA patients and decreases in the mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the mean Ankylosing Spondylitis Disease Activity Score (ASDAS) in axSpA patients. This improvement was maintained or increased after 2 and 3 years of treatment, indicating that secukinumab is effective in both naïve and non-responder patients. Retention rates were higher when secukinumab was used as the first-line biological treatment, although they were also adequate in the second and third lines of treatment. Collected safety data were consistent with previous reports.
- Open Access
- 13 November 2019
- Published by American Society of Hematology in Blood
- Vol. 134 (Supplement) , 3874
Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblstic Leukemia. Preliminary Results of Ponalfil Clinical Trial
Background and objective. The combination of tyrosine kinase inhibitors (TKI) and chemotherapy (intensive, attenuated or minimal) has improved the prognosis of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). The combination of HyperCVAD and ponatinib has improved the molecular response and survival compared with other combinations of chemotherapy and first or second generation tyrosine kinase inhibitors (TKI) (Jabbour, et al, Lancet Haematol. 2018; 5:e618-e627). The Spanish PETHEMA group conducts the phase 2 PONALFIL trial, that incorporates ponatinib to the same induction and consolidation schedule of the ALL Ph08 trial (Ribera JM et al. Cancer 2019. doi:10.1002/cncr.32156). The preliminary results of this trial are herein reported. Patients and method. The PONALFIL trial (NCT02776605) combines ponatinib (30 mg/d) and induction chemotherapy (vincristine, daunorubicin and prednisone) followed by consolidation (high-dose methotrexate, ARA-C, mercaptopurine, etoposide) and allogeneic HSCT in de novo Ph+ ALL patients aged 18-60 years. Regular molecular follow-up was performed after alloHSCT. No TKI after HSCT was planned unless persistence or reappearance of molecular disease. On July 2019, 21 out of the 30 patients had been recruited. Molecular studies were centrally carried out according to the Euro-MRD consortium on standardization (Pfeifer et al, Leukemia, 2019; PMID: 30858550). The response to therapy (complete morphological [CR], molecular [complete, CMR or major, MMR] after induction and before allogeneic HSCT), CR duration, overall survival [OS]) and toxicity in the first 21 cases is herein analyzed. Results. Median age was 49 (19-59) years and 12 patients were female. One patient showed CNS involvement at diagnosis. Median WBC count was 12.4 (0.6-79.5) x109/L, Hb 87 (71-140) g/L, platelets 39 (15-180) x109/L. The immunologic phenotype was common in 13 cases, with molecular isoform p190 in 14 patients (67%), p210(b2a2) in 6 (21%) and p210(b3a2) in the remaining patient. CR was attained in 19/19 patients (2 are still on induction therapy), with CMR in 9/18 cases (50%), MMR in 4/18 (22%) and no molecular response in 5/18 (28%) (molecular response analysis pending in 1 patient). Six patients are receiving consolidation, 5 are waiting for allogeneic HSCT and 6 patients have been transplanted (4 in CMR, 1 in MMR, 1 with no data). At the time of the study one patient showed molecular relapse after allogeneic HSCT and is receiving ponatinib, whereas the remaining patients are alive and in CR1 (median follow-up of 3.7 months, range 0.3-18.2) Sixty-nine adverse events (AE) have been registered in 9 patients, 8 of whom were severe (SAE) and occurred in 6 patients, prompting to withdrawn of the trial in 2 (thrombosis of the retinal central artery and severe bowel infection, one case each). The most frequent AE were hematologic (25%), gastrointestinal (14%), infections (7%), and cutaneous (7%). Cardiovascular events occurred in 2 patients (angor pectoris and thrombosis of central artery of the retina, one case each). Conclusions. The preliminary results of the PONALFIL trial show a high short-term antileukemic efficacy with acceptable toxicity profile.
- 13 November 2019
- Published by American Society of Hematology in Blood
- Vol. 134 (Supplement) , 3874
Open AccessPonatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblstic Leukemia. Preliminary Results of Ponalfil Clinical Trial
Background and objective. The combination of tyrosine kinase inhibitors (TKI) and chemotherapy (intensive, attenuated or minimal) has improved the prognosis of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). The combination of HyperCVAD and ponatinib has improved the molecular response and survival compared with other combinations of chemotherapy and first or second generation tyrosine kinase inhibitors (TKI) (Jabbour, et al, Lancet Haematol. 2018; 5:e618-e627). The Spanish PETHEMA group conducts the phase 2 PONALFIL trial, that incorporates ponatinib to the same induction and consolidation schedule of the ALL Ph08 trial (Ribera JM et al. Cancer 2019. doi:10.1002/cncr.32156). The preliminary results of this trial are herein reported. Patients and method. The PONALFIL trial (NCT02776605) combines ponatinib (30 mg/d) and induction chemotherapy (vincristine, daunorubicin and prednisone) followed by consolidation (high-dose methotrexate, ARA-C, mercaptopurine, etoposide) and allogeneic HSCT in de novo Ph+ ALL patients aged 18-60 years. Regular molecular follow-up was performed after alloHSCT. No TKI after HSCT was planned unless persistence or reappearance of molecular disease. On July 2019, 21 out of the 30 patients had been recruited. Molecular studies were centrally carried out according to the Euro-MRD consortium on standardization (Pfeifer et al, Leukemia, 2019; PMID: 30858550). The response to therapy (complete morphological [CR], molecular [complete, CMR or major, MMR] after induction and before allogeneic HSCT), CR duration, overall survival [OS]) and toxicity in the first 21 cases is herein analyzed. Results. Median age was 49 (19-59) years and 12 patients were female. One patient showed CNS involvement at diagnosis. Median WBC count was 12.4 (0.6-79.5) x109/L, Hb 87 (71-140) g/L, platelets 39 (15-180) x109/L. The immunologic phenotype was common in 13 cases, with molecular isoform p190 in 14 patients (67%), p210(b2a2) in 6 (21%) and p210(b3a2) in the remaining patient. CR was attained in 19/19 patients (2 are still on induction therapy), with CMR in 9/18 cases (50%), MMR in 4/18 (22%) and no molecular response in 5/18 (28%) (molecular response analysis pending in 1 patient). Six patients are receiving consolidation, 5 are waiting for allogeneic HSCT and 6 patients have been transplanted (4 in CMR, 1 in MMR, 1 with no data). At the time of the study one patient showed molecular relapse after allogeneic HSCT and is receiving ponatinib, whereas the remaining patients are alive and in CR1 (median follow-up of 3.7 months, range 0.3-18.2) Sixty-nine adverse events (AE) have been registered in 9 patients, 8 of whom were severe (SAE) and occurred in 6 patients, prompting to withdrawn of the trial in 2 (thrombosis of the retinal central artery and severe bowel infection, one case each). The most frequent AE were hematologic (25%), gastrointestinal (14%), infections (7%), and cutaneous (7%). Cardiovascular events occurred in 2 patients (angor pectoris and thrombosis of central artery of the retina, one case each). Conclusions. The preliminary results of the PONALFIL trial show a high short-term antileukemic efficacy with acceptable toxicity profile.
- 1 November 2019
- Published by Elsevier in Reumatología Clínica
- Vol. 15 (6) , 360-362
Relationship between fecal calprotectin, anti-Saccharomyces cerevisiae antibodies and other markers of disease activity in patients with spondyloarthritis
- 1 November 2019
- Published by Elsevier in Reumatología Clínica
- Vol. 15 (6) , 360-362
Relationship between fecal calprotectin, anti-Saccharomyces cerevisiae antibodies and other markers of disease activity in patients with spondyloarthritis
- 1 March 2019
- Published by Elsevier in Reumatología Clínica
- Vol. 15 (2) , 90-96
Prevalencia de enfermedades reumáticas en población adulta en España (estudio EPISER 2016). Objetivos y metodología
- 1 March 2019
- Published by Elsevier in Reumatología Clínica
- Vol. 15 (2) , 90-96
Prevalencia de enfermedades reumáticas en población adulta en España (estudio EPISER 2016). Objetivos y metodología
- Open Access
- 1 June 2018
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 77 (Suppl 2) , 1867
AB1473-HPR Quality of referral letters received in rheumatology
Background The referral letter is an essential tool in the relationship between Primary Care and other specialties with Rheumatology. In our area, in 2010, a computer system called SELENE was introduced at hospital level and, in Primary Care, O.M.I. was set up more than 20 years ago Objectives To assess the quality of referral letters received in the Rheumatology Unit during the first four months of 2017 Methods Retrospective and descriptive study, in which referral letters received in the Rheumatology Unit between January and April 2017 were analysed. The following variables were collected: medical specialty that sent the document, computerization of the document, reference to medical history, chronic treatments, current disease, physical examination, complementary tests, presumption diagnosis, treatment for the current process, and number of reasons for consultation per document. The quality of the document was assessed using the recommendations of Irazábal and Gutiérrez modified by Morera et al, which classified them as: good, acceptable and bad (table 1). Quality of referral letters. Good It includes medical history, familiar medical history, chronic treatment, current disease, complementary tests, presumption diagnosis, differential diagnosis and reason for consultation Acceptable It includes reason for consultation and enough information about current disease, although not all those included in the previous one Bad Unreadable, without enough information to assess the current disease or absence of information In the descriptive statistical analysis of quantitative variables, the mean and standard deviation were used. Frequencies were used to analyse qualitative variables Results 1234 referral letters were included and 90.3% were computerised. The specialties that referred patients more frequently were: Primary Care (84.7%), Traumatology (3.4%), Neurology (1.9%) and Emergency (1.6%). 14.5% of the documents included more than one reason for consultation. The variables related to the fulfilment of quality criteria in the referral letters are shown in Table 2. Regarding the quality level, 4.1% of the documents were good, 95.2% acceptable and 0.6% bad. Quality criteria in the referral letters Conclusions The quality of the referral letters was mostly acceptable. Therefore, there is much room to improve, especially in the sections referencing medical history, chronic treatment, physical examination and treatment for the current process Disclosure of Interest None declared
- 1 June 2018
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 77 (Suppl 2) , 1867
Open AccessAB1473-HPR Quality of referral letters received in rheumatology
Background The referral letter is an essential tool in the relationship between Primary Care and other specialties with Rheumatology. In our area, in 2010, a computer system called SELENE was introduced at hospital level and, in Primary Care, O.M.I. was set up more than 20 years ago Objectives To assess the quality of referral letters received in the Rheumatology Unit during the first four months of 2017 Methods Retrospective and descriptive study, in which referral letters received in the Rheumatology Unit between January and April 2017 were analysed. The following variables were collected: medical specialty that sent the document, computerization of the document, reference to medical history, chronic treatments, current disease, physical examination, complementary tests, presumption diagnosis, treatment for the current process, and number of reasons for consultation per document. The quality of the document was assessed using the recommendations of Irazábal and Gutiérrez modified by Morera et al, which classified them as: good, acceptable and bad (table 1). Quality of referral letters. Good It includes medical history, familiar medical history, chronic treatment, current disease, complementary tests, presumption diagnosis, differential diagnosis and reason for consultation Acceptable It includes reason for consultation and enough information about current disease, although not all those included in the previous one Bad Unreadable, without enough information to assess the current disease or absence of information In the descriptive statistical analysis of quantitative variables, the mean and standard deviation were used. Frequencies were used to analyse qualitative variables Results 1234 referral letters were included and 90.3% were computerised. The specialties that referred patients more frequently were: Primary Care (84.7%), Traumatology (3.4%), Neurology (1.9%) and Emergency (1.6%). 14.5% of the documents included more than one reason for consultation. The variables related to the fulfilment of quality criteria in the referral letters are shown in Table 2. Regarding the quality level, 4.1% of the documents were good, 95.2% acceptable and 0.6% bad. Quality criteria in the referral letters Conclusions The quality of the referral letters was mostly acceptable. Therefore, there is much room to improve, especially in the sections referencing medical history, chronic treatment, physical examination and treatment for the current process Disclosure of Interest None declared